Andreas Frick is research director at the Institut National de la Santé et de la Recherche Médicale (INSERM), the French equivalent of the National Institutes of Health, and he has headed the Cortical Plasticity Group at the Neurocentre Magendie (Bordeaux, France) since 2008. His team is a member of the Bordeaux Neuroscience Excellence Cluster and Bordeaux Neurocampus.
He obtained a Ph.D. in neuroscience at the Max Planck Institute for Psychiatry and the Technical University of Munich (Germany). He performed his postdoctoral research with Daniel Johnston at Baylor College of Medicine (Houston, Texas), followed by a research group leader position at the Max Planck Institute for Medical Research (Heidelberg, Germany), headed by Nobel Laureate Bert Sakmann.
Frick is an internationally recognized expert in the use of preclinical models for studying neocortical dysfunction in neurodevelopmental disorders. The long-term goal of his work is to identify novel mechanisms underlying neocortical dysfunction and to develop mechanism-based therapeutic strategies to treat neurodevelopmental and psychiatric disorders.
His major contributions to the field have been highlighted in newspapers (including Le Figaro) and specialist magazines and in public forums on autism research. His work is also cited as support for clinical trials using a large-conductance calcium-activated potassium channel (BKCa) opener. In 2019, he obtained the Marcel Dassault Prize for innovative research in mental health disorders.